Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humacyte鈥檚 SEC disclosures can span hundreds of pages, laced with clinical data tables, FDA correspondence, and R&D spending notes that even seasoned biotech analysts need time to decode. Whether you are tracking cash runway before the next phase III read-out or monitoring Humacyte insider trading Form 4 transactions, finding the right line item quickly is a real challenge.
Stock Titan solves that problem by pairing every 10-K, 10-Q, 8-K, S-1, and proxy statement with AI-powered summaries that translate technical language into clear insights. Want the key takeaways from the latest Humacyte quarterly earnings report 10-Q filing? Our engine highlights trial costs, milestone payments, and dilution risk in seconds. Need to know when executives file the next Humacyte executive stock transactions Form 4? AG真人官方-time alerts appear the moment the document hits EDGAR. From Humacyte 8-K material events explained to the Humacyte annual report 10-K simplified, every filing is searchable, linked, and summarized.
Use the platform to:
- Compare quarter-over-quarter R&D spend without scrolling through footnotes.
- Follow Humacyte proxy statement executive compensation to understand incentive alignment.
- See Humacyte earnings report filing analysis alongside market-moving 8-K disclosures.
- Receive Humacyte Form 4 insider transactions real-time so you never miss strategic buying or selling.
With comprehensive coverage and expert analysis that helps investors understand complex documents, Stock Titan makes understanding Humacyte SEC documents with AI straightforward鈥攕o you can spend more time acting on information, not hunting for it.
Humacyte reported early commercial activity for Symvess and maintained meaningful liquidity while continuing R&D spending. Cash and cash equivalents were $38.0 million with restricted cash of $50.2 million, totaling $88.4 million of cash and restricted cash. Total assets were $138.8 million and stockholders' equity was $4.1 million. The company recognized product and contract revenue of $0.3 million in Q2 2025 and $0.8 million for the six months ended June 30, 2025, and capitalized $11.1 million of inventory related to Symvess.
Operating expenses remained high: R&D was $37.4 million for six months and the operating loss was $52.9 million for the same period. Net results for the six months show a $1.5 million net income driven largely by a $44.3 million favorable change in the fair value of a contingent earnout liability, while the three鈥憁onth period posted a $37.7 million net loss. Financing activity included a $46.7 million public offering (net) and ATM proceeds of $3.6 million in the first half of 2025. The company implemented workforce reductions and expects existing cash plus available equity commitments to fund operations for at least twelve months from these interim statements.
Humacyte, Inc. furnished a press release reporting its financial results for the fiscal second quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Current Report, but the body of the Form 8-K does not include the underlying financial figures or tables.
The filing explicitly states that the information, including the exhibit, "shall not be deemed filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference in other filings except by specific reference. The report also identifies the company as an emerging growth company and lists its securities as Common Stock (HUMA) and Redeemable Warrants (HUMAW) on Nasdaq. The filing includes Exhibit 99.1 and the Cover Page Interactive Data File (Exhibit 104).
FAQ
What is the current stock price of Humacyte (HUMA)?
What is the market cap of Humacyte (HUMA)?
